European Markets for Benign Prostatic Hyperplasia Therapies
This article was originally published in Start Up
Investor interest in the urology space waxes and wanes; it's attractive because as a niche specialty it has some pretty big patient populations. Benign prostatic hyperplasia (BPH), the benign enlargement of the prostate over time, affects 90% of men by the time they're 80, and half of men at age 60. In Europe, according to European Markets for Benign Prostatic Hyperplasia Drugs, Devices, and Therapies, a report recently published by FDC-Windhover Information's Medtech Insight division, that's 28 million men. But urology goes out of favor from time to time because so many drugs and device therapies that initially looked promising failed to address the majority of BPH sufferers, or worse, caused side effects in a very sensitive part of the body. Now, we seem to be heading into an up-cycle for BPH, in both the device and pharmaceutical segments.
You may also be interested in...
Serving the aging US demographic is a golden opportunity for urology device companies. However, at this year's meeting of the American Urological Association, the field concentrated more on consolidation of older techniques than on breakthrough technologies.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.
The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.